{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:34:11Z","timestamp":1781822051286,"version":"3.54.5"},"reference-count":51,"publisher":"FapUNIFESP (SciELO)","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  BACKGROUND:  Chronic hepatitis C still figures as an important cause of morbidity among the Brazilian population, and is closely associated with metabolic disturbances, including insulin resistance (IR), which can be evaluated by the Homeostatic Model Assessment (HOMA-IR). IR may entail lower sustained virologic response (SVR) on certain therapeutic regimens and faster progression to advanced hepatic fibrosis. With the arrival of the direct acting agents (DAA) in hepatitis C treatment, there is an increased need in observing the impact in patients\u2019 IR profile while using such therapies.  OBJECTIVE:  - 1) To compare the results of HOMA-IR in patients affected by chronic hepatitis C before treatment with DAA and 12 months after finishing it with SVR. 2) To evaluate the evolution of weight after curing chronic hepatitis C.  METHODS:  We included patients older than 18 from two tertiary care in Curitiba - PR, of both sexes, with chronic hepatitis C, treated with DAA, from July 2015 to September 2017. We also evaluated the patients\u2019 levels of fasting insulin, fasting glucose and glycated hemoglobin before starting treatment and 12 months after finishing it. We also used epidemiologic data, such as age, sex, hepatic fibrosis degree, body mass index, abdominal circumference, viral genotype and the presence of diabetes mellitus before and after treatment. IR was assessed before and after treatment and calculated by the HOMA-IR score. Insulin resistance was defined by a HOMA-IR greater than 2.5. We excluded patients who lost follow-up, those who did not achieve SRV and those who did not have a laboratory profile. The results of quantitative variables were described by means, medians, and standard deviations. P values &lt;0.05 indicated statistical significance.  RESULTS:  We included 75 patients in this study, with a mean age of 55.2 years and 60% of males. Forty-three patients had advanced fibrosis. Twenty one (28%) had a previous diabetes mellitus diagnosis. We identified 31 (41.3%) patients with IR before antiviral treatment, and this number increased to 39 (52%) after 12 months of finishing treatment, according to HOMA-IR. There was no statistic difference between insulin, glucose and HOMA-IR measurements before and after curing hepatitis C. We observed a weight gain in patients shortly after curing hepatitis C, but this did not persist at the end of the study. We also had no significant difference in IR prevalence when viral genotype was concerned.  CONCLUSION:  In this study, there was no statistically significant difference between HOMA-IR results in patients before and 12 months after treatment for hepatitis C. Even though patients gained weight after the cure, this was not statistically significant after a year (P=0.131).<\/jats:p>","DOI":"10.1590\/s0004-2803.202000000-50","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T21:27:43Z","timestamp":1601674063000},"page":"267-271","source":"Crossref","is-referenced-by-count":8,"title":["CURING HEPATITIS C WITH THE NEW DIRECT ACTING ANTIVIRALS DID NOT IMPROVE INSULIN RESISTANCE AFTER ONE YEAR"],"prefix":"10.1590","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8346-1598","authenticated-orcid":false,"given":"Lohanna","family":"STRAUHS-NITSCH","sequence":"first","affiliation":[{"name":"Hospital Nossa Senhora das Gra\u00e7as,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7340-2495","authenticated-orcid":false,"given":"Marcela Ferro","family":"CAMPIOLO","sequence":"additional","affiliation":[{"name":"Hospital Nossa Senhora das Gra\u00e7as,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1060-7431","authenticated-orcid":false,"given":"Daphne Benatti Gon\u00e7alves","family":"MORSOLETTO","sequence":"additional","affiliation":[{"name":"Hospital Nossa Senhora das Gra\u00e7as,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9573-9438","authenticated-orcid":false,"given":"Alcindo","family":"PISSAIA JUNIOR","sequence":"additional","affiliation":[{"name":"Hospital Nossa Senhora das Gra\u00e7as,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-557X","authenticated-orcid":false,"given":"Claudia Alexandre Pontes","family":"IVANTES","sequence":"additional","affiliation":[{"name":"Hospital Nossa Senhora das Gra\u00e7as,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2020,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jdiacomp.2006.01.001","article-title":"Hepatitis C infection and diabetes","volume":"20","author":"Noto H","year":"2006","journal-title":"J Diabetes Complications"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0168-8278(05)80631-2","article-title":"Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population","volume":"21","author":"Allison ME","year":"1994","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/hep.22251","article-title":"Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus","volume":"47","author":"Veldt BJ","year":"2008","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/hep.25867","article-title":"Sustained virological response prevents the development of insulin resistance in patients with chronic hepatites C","volume":"56","author":"Aghemo A","year":"2012","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","article-title":"Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression","volume":"125","author":"Hui JM","year":"2003","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1464-5491.1995.tb00466.x","article-title":"High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests","volume":"12","author":"Gray H","year":"1995","journal-title":"Diabet Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2796.1994.tb01075.x","article-title":"Increased prevalence of hepatitis C v\u00edrus antibodies in patients with diabetes mellitus","volume":"235","author":"Ozyilkan E","year":"1994","journal-title":"J Intern Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0168-8278(01)00143-X","article-title":"Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C","volume":"35","author":"Petit JM","year":"2001","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/diacare.19.9.998","article-title":"High prevalence of hepatitis C virus infection in diabetic patients","volume":"19","author":"Simo R","year":"1996","journal-title":"Diabetes Care"},{"key":"ref10","first-page":"141","article-title":"Association of chronic hepatitis C infection and diabetes mellitus","volume":"19","author":"El-Zayadi AR","year":"1998","journal-title":"Trop Gastroenterol"},{"key":"ref11","first-page":"283","article-title":"High prevalence of diabetes mellitus in patients with chronic hepatitis C: A case control study","volume":"235","author":"Grimbert S","year":"1996","journal-title":"Gastroenterol Clin Biol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4065\/75.4.355","article-title":"Increased risk of type 2 diabetes in non-cirrhotic patients with chronic hepatitis C virus infection","volume":"75","author":"Knobler H","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-133-8-200010170-00009","article-title":"Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States","volume":"133","author":"Mehta SH","year":"2000","journal-title":"Ann Intern Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jhep.2008.08.006","article-title":"Hepatitis C infection and risk of diabetes: a systematic reiew and meta-analysis","volume":"49","author":"White DL","year":"2008","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3748\/wjg.15.1537","article-title":"Hepatitis C virus and type 2 diabetes","volume":"15","author":"Negro F","year":"2009","journal-title":"World J Gastroenterol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4239\/wjd.v5.i5.586","article-title":"Hepatitis C virus infection and type 1 and type 2 diabetes mellitus","volume":"5","author":"Antonelli A","year":"2014","journal-title":"World J Diabetes"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1023\/A:1014715327729","article-title":"Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C","volume":"47","author":"Tazawa J","year":"2002","journal-title":"Dig Dis Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2362.2000.00608.x","article-title":"Evaluation of factors controlling glucose tolerance in patients with HC infection before and after 4 months therapy with interferon-alpha","volume":"30","author":"Konrad T","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jhep.2014.08.003","article-title":"Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases","volume":"61","author":"Negro F","year":"2014","journal-title":"J Hepatol"},{"key":"ref20","first-page":"335","article-title":"Changes in glucose tolerance after interferon alpha therapy in patients with chronic hepatitis C","volume":"28","author":"Tanaka H","year":"1997","journal-title":"J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1002\/j.1460-2075.1996.tb01045.x","article-title":"Mechanism of activation of protein kinase B by insulin and IGF-1","volume":"15","author":"Alessi DR","year":"1996","journal-title":"EMBO J"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1128\/JVI.01672-07","article-title":"Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt\/protein kinase B signalling pathway for insulin resistance","volume":"82","author":"Banerjee S","year":"2008","journal-title":"J Virol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/eje.0.1460419","article-title":"Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes","volume":"146","author":"Bur\u00e9n J","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0002-9440(10)63408-6","article-title":"Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3","volume":"165","author":"Kawaguchi T","year":"2004","journal-title":"Am J Pathol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signalling: navigating downstream","volume":"129","author":"Manning BD","year":"2007","journal-title":"Cell"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/hep.21634","article-title":"The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms","volume":"45","author":"Pazienza V","year":"2007","journal-title":"Hepatology"},{"key":"ref27","first-page":"1266","article-title":"Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity","volume":"36","author":"Adinolfi LE","year":"2002","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1046\/j.1440-1746.2002.02813.x","article-title":"Genotype specific mechanisms for hepatic steatosis in chronic hepatitis C infection","volume":"17","author":"Hui JM","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1053\/jhep.2002.36370","article-title":"Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response","volume":"36","author":"Kumar D","year":"2002","journal-title":"Hepatology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.510290235","article-title":"Association of diabetes mellitus and chronic hepatitis C infection","volume":"29","author":"Mason AL","year":"1999","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.2337\/dc15-S005","article-title":"Diagnosis and classification of diabetes mellitus","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"ref32","series-title":"Diretrizes da Sociedade Brasileira de Diabetes (2015-2016)","author":"Milech Adolfo","year":"2016"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1590\/S0004-27302007000900014","article-title":"S\u00edndrome Metab\u00f3lica, seus fen\u00f3tipos e resist\u00eancia \u00e0 insulina pelo HOMA-RI","volume":"51","author":"Oliveira EP","year":"2007","journal-title":"Arq Bras Endocrinol Metab"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1053\/meta.2000.7735","article-title":"The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin dependent diabetic patients","volume":"49","author":"Taniguchi A","year":"2000","journal-title":"Metabolism"},{"key":"ref35","first-page":"67","article-title":"Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature","volume":"34","author":"Fabiani S","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cld.2017.03.004","article-title":"Metabolic Manifestations of Hepatitis C Virus: Diabetes Mellitus, Dyslipidemia","volume":"21","author":"Serfaty L","year":"2017","journal-title":"Clin Liver Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"9513","DOI":"10.1002\/jcb.27267","article-title":"Study on the relationship between insulin growth factor 1 and liver fibrosis in patients with chronic hepatitis C with type 2 diabetes mellitus","volume":"119","author":"Cao LH","year":"2018","journal-title":"J Cell Biochem"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.kjms.2012.11.001","article-title":"Glucose abnormalities in hepatitis C virus infection","volume":"29","author":"Huang JF","year":"2013","journal-title":"Kaohsiung J Med Sci"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.15403\/jgld.2014.1121.273.daa","article-title":"Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C","volume":"27","author":"Weidner P","year":"2018","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"6150861","DOI":"10.1155\/2018\/6150861","article-title":"Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy","volume":"2018","author":"Drazilova S","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4254\/wjh.v10.i9.612","article-title":"Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves haemoglobin A1c","volume":"10","author":"Dong TS","year":"2018","journal-title":"World J Hepatol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijcard.2018.04.058","article-title":"Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function","volume":"271","author":"Schmidt FP","year":"2018","journal-title":"Int J Cardiol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jare.2016.06.001","article-title":"Hepatitis C virus and cardiovascular: A review","volume":"8","author":"Petta S","year":"2017","journal-title":"J Adv Res"},{"key":"ref44","first-page":"3116","article-title":"Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment","author":"Elhelbawy M","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jmv.24954","article-title":"Significant improvement of glycaemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents","volume":"90","author":"Ciancio A","year":"2018","journal-title":"J Med Virol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5604\/16652681.1231581","article-title":"Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C","volume":"16","author":"Stine JG","year":"2017","journal-title":"Ann. Hepatol"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/infdis\/jix517","article-title":"No Improvement in Haemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV","volume":"217","author":"Chaudhury CS","year":"2018","journal-title":"J Infect Dis"},{"key":"ref48","series-title":"J Viral Hepatol","first-page":"188","volume":"27","author":"Russo FP","year":"2020"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1590\/s0004-2803.201800000-69","article-title":"Insulin resistance reduction after sustained virological response with direct acting antiviral: not every population improves","volume":"55","author":"Andrade VG","year":"2018","journal-title":"Arq Gastroenterol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/gut.2010.236158","article-title":"Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2\/3","volume":"61","author":"Thompson AJ","year":"2012","journal-title":"Gut"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"15233","DOI":"10.3748\/wjg.v20.i41.15233","article-title":"Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3","volume":"20","author":"Abenavoli L","year":"2014","journal-title":"World J Gastroenterol"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v57n3\/1678-4219-ag-s0004280320200000050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T04:13:28Z","timestamp":1611461608000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032020000300267&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["S0004-28032020000300267"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.202000000-50","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}